Pfizer LimitedPFIZERCorporate

Healthcare Drug Manufacturers - General Latest results: Jun 2026 2 quarters of data

₹3,814.00

MCap ₹17,448 Cr

Pfizer Limited — Stock analysis & AI research Pfizer Limited — Multibagger AI analysis Pfizer Limited — Seasonality — best & worst months Pfizer Limited — Technical indicators & charts Pfizer Limited — Technical setup — score, trend, support & resistance Pfizer Limited — Falling Wedge pattern forming Pfizer Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 Stocks Cheaper Than Their Industry 📋 Low Debt Stocks 📋 Small Cap Stocks List 📈 SuperTrend Bullish Signal 📈 Lowest Technical Score 📈 Multi-Timeframe Bearish Stocks 📈 Stocks Near 52-Week Low ⚖️ vs Abbott India ⚖️ vs GlaxoSmithKline Pharmaceuticals 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹653 Cr

Sales · Jun 2026

₹248 Cr

Operating Profit · Jun 2026

37.9%

OPM % · Jun 2026

₹204 Cr

Net Profit · Jun 2026

₹44.69

EPS · Jun 2026

📝 Pfizer Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Pfizer Limited reported revenue of ₹653 crore for the quarter ended June 2026 (Q1 FY27).

Net profit stood at ₹204 crore. Earnings per share (EPS) came in at ₹44.69.

Operating profit stood at ₹248 crore — an operating margin (OPM) of 37.9%.

Valuation snapshot

At the current price of ₹3,814.00, PFIZER has a market capitalisation of ₹17,448 crore.

Within the Drug Manufacturers - General industry, it is the 3rd-largest of the 5 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 63.92%, foreign institutional investors (FIIs) 1.63%, domestic institutional investors (DIIs) 17.52%, public shareholders 16.92% of Pfizer Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹17,448 Cr

Current Price ?

₹3,814.0

P/E ?

N/A

Industry P/E ?

62.30

P/B ?

4.15

P/S ?

N/A

P/FCF ?

18.48

Enterprise Value ?

₹17,518 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

1.97%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

24.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹653 Cr

PAT — latest qtr ?

₹204 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹70 Cr

Debt to Equity ?

0.02

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

63.92%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-16.5%

Return 6 months ?

-23.1%

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2025	Jun 2026	YoY %	QoQ %
Sales	645	653	—	—
Operating Profit	228	248	—	—
Other Income	38	45	—	—
Interest	2	1	—	—
Depreciation	14	14	—	—
Profit Before Tax	192	277	—	—
Net Profit	142	204	—	—
EPS	31.01	44.69	—	—
OPM %	35.4%	37.9%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	46	46	46	46	+0.0%
Reserves	3,162	3,550	4,172	4,157	-0.4%
Borrowings	41	40	41	70	+70.7%
Other Liabilities	752	593	653	649	-0.6%
Total Liabilities	4,001	4,229	4,911	4,922	+0.2%
Fixed Assets	749	713	724	678	-6.4%
CWIP	8	0	8	20	+150.0%
Investments	0	0	0	0	—
Other Assets	3,244	3,516	4,180	4,224	+1.1%
Total Assets	4,001	4,229	4,911	4,922	+0.2%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	356	257	660	968	+46.7%
Cash from Investing Activity	-36	54	-71	-562	-691.5%
Cash from Financing Activity	-346	-235	-205	-798	-289.3%
Net Cash Flow	-26	75	383	-392	-202.3%
Free Cash Flow	292	291	783	944	+20.6%
CFO/OP	81%	64%	110%	105%	-4.5%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	23	31	31	26	-16.1%
Inventory Days	175	200	214	195	-8.9%
Days Payable	91	77	68	89	+30.9%
Cash Conversion Cycle	107	154	177	132	-25.4%
Working Capital Days	1	24	23	9	-60.9%
ROCE %	26%	22%	22%	24%	+9.1%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	63.92%	63.92%	63.92%	63.92%	63.92%	+0.0%
FIIs	2.40%	2.60%	2.71%	2.81%	1.63%	-42.0%
DIIs	17.23%	17.11%	17.05%	16.89%	17.52%	+3.7%
Public	16.45%	16.37%	16.32%	16.36%	16.92%	+3.4%
No. of Shareholders	1,03,222	1,03,480	1,00,933	99,545	1,04,472	+4.9%

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	GLAXO GlaxoSmithKline Pharmaceuticals	₹2,818.90	47,754	44.7	3,955	1,068	40.8%	27.0%	1.9%	11.6%	16.6%	15.7%
2	RUBICON RUBICON RESEARCH	₹1,839.40	30,367	103.7	1,936	288	23.3%	14.9%	—	—	51.8%	97.2%
3	PFIZER Pfizer	₹4,055.00	18,551	25.2	2,569	735	36.7%	28.6%	10.4%	-5.8%	8.3%	6.2%
4	SAIPARENT Sai Parenterals	₹498.00	2,200	—	—	—	—	—	—	—	435.1%	458.0%
5	SYMBIOTEC Symbiotec Pharmalab	₹1,107.00	—	—	—	—	—	—	—	—	7.5%	-53.1%

❓ Frequently asked questions

What was Pfizer Limited's revenue in Q1 FY27?